Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?

被引:1
|
作者
Leite-Silva, Jessica [1 ]
Oliveira-Ribeiro, Carla [2 ]
Morgado, Fernanda Nazare [1 ]
Pimentel, Maria Ines Fernandes [3 ]
Lyra, Marcelo Rosandiski [3 ]
Fagundes, Aline [3 ]
Miranda, Luciana Freitas Campos [3 ]
Valete-Rosalino, Claudia Maria [3 ]
Schubach, Armando Oliveira [3 ]
Conceicao-Silva, Fatima [1 ]
机构
[1] Fundacao Oswaldo Cruz Fiocruz, Oswaldo Cruz Inst IOC, Lab Immunoparasitol, BR-21041250 Rio De Janeiro, RJ, Brazil
[2] Natl Inst Canc INCA, Serv Oncol Dermatol, BR-20570120 Rio De Janeiro, RJ, Brazil
[3] Natl Inst Infectol Evandro Chagas INI, Lab Clin Res & Surveillance Leishmaniasis, LAPCLIN VIGILEISH, BR-21041250 Fiocruz Rio De Janeiro, RJ, Brazil
关键词
host-parasite interaction; immunopathology; cutaneous leishmaniasis; spontaneous healing; treatment relapse; in situ immune response; macrophages; cell-mediated immunity; immunohistochemistry; CD163; NEUTROPHIL EXTRACELLULAR TRAPS; RIO-DE-JANEIRO; NITRIC-OXIDE; T-CELLS; ANTIINFLAMMATORY CYTOKINES; INFLAMMATORY REACTION; MAJOR INFECTION; MACROPHAGE; EXPRESSION; FAILURE;
D O I
10.3390/microorganisms11071631
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Localized cutaneous leishmaniasis caused by Leishmania braziliensis can either respond well or poorly to the treatment or heal spontaneously; It seems to be dependent on the parasite and/or host factors, but the mechanisms are not fully understood. We evaluated the in situ immune response in eighty-two active lesions from fifty-eight patients prior to treatment classified as early spontaneous regression (SRL-n = 14); treatment responders (GRL-n = 20); and non-responders (before first treatment/relapse, PRL1/PRL2-n = 24 each). Immunohistochemistry was used to identify cell/functional markers which were correlated with the clinical characteristics. PRL showed significant differences in lesion number/size, clinical evolution, and positive parasitological examinations when compared with the other groups. SRL presented a more efficient immune response than GRL and PRL, with higher IFN-& gamma;/NOS2 and a lower percentage of macrophages, neutrophils, NK, B cells, and Ki-67+ cells. Compared to SRL, PRL had fewer CD4+ Tcells and more CD163+ macrophages. PRL1 had more CD68+ macrophages and Ki-67+ cells but less IFN-& gamma; than GRL. PRL present a less efficient immune profile, which could explain the poor treatment response, while SRL had a more balanced immune response profile for lesion healing. Altogether, these evaluations suggest a differentiated profile of the organization of the inflammatory process for lesions of different tegumentary leishmaniasis evolution.
引用
收藏
页数:21
相关论文
共 3 条
  • [1] Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
    Perez-Franco, Jairo E.
    Cruz-Barrera, Monica L.
    Robayo, Marta L.
    Lopez, Myriam C.
    Daza, Carlos D.
    Bedoya, Angela
    Marino, Maria L.
    Saavedra, Carlos H.
    Echeverry, Maria C.
    PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (05):
  • [2] Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study
    Gagini, Thalita
    Schubach, Armando de Oliveira
    Madeira, Maria de Fatima
    Valete-Rosalino, Claudia Maria
    Fernandes Pimentel, Maria Ines
    Pacheco, Raquel da Silva
    PARASITE, 2017, 24
  • [3] Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways
    Bamorovat, Mehdi
    Sharifi, Iraj
    Aflatoonian, Mohammad Reza
    Sadeghi, Balal
    Shafiian, Alireza
    Oliaee, Razieh Tavakoli
    Keyhani, Alireza
    Afshar, Abbas Aghaei
    Khosravi, Ahmad
    Mostafavi, Mahshid
    Parizi, Maryam Hakimi
    Khatami, Mehrdad
    Arefinia, Nasir
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 69 : 321 - 327